JP2007526998A5 - - Google Patents

Download PDF

Info

Publication number
JP2007526998A5
JP2007526998A5 JP2006549676A JP2006549676A JP2007526998A5 JP 2007526998 A5 JP2007526998 A5 JP 2007526998A5 JP 2006549676 A JP2006549676 A JP 2006549676A JP 2006549676 A JP2006549676 A JP 2006549676A JP 2007526998 A5 JP2007526998 A5 JP 2007526998A5
Authority
JP
Japan
Prior art keywords
substituted
values
less
formula
glucuronide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006549676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007526998A (ja
JP4590417B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/001469 external-priority patent/WO2005069900A2/en
Publication of JP2007526998A publication Critical patent/JP2007526998A/ja
Publication of JP2007526998A5 publication Critical patent/JP2007526998A5/ja
Application granted granted Critical
Publication of JP4590417B2 publication Critical patent/JP4590417B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006549676A 2004-01-16 2005-01-14 Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法 Expired - Fee Related JP4590417B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53734104P 2004-01-16 2004-01-16
PCT/US2005/001469 WO2005069900A2 (en) 2004-01-16 2005-01-14 Npc1l1 (npc3) and methods of identifying ligands thereof

Publications (3)

Publication Number Publication Date
JP2007526998A JP2007526998A (ja) 2007-09-20
JP2007526998A5 true JP2007526998A5 (https=) 2008-02-28
JP4590417B2 JP4590417B2 (ja) 2010-12-01

Family

ID=34807095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549676A Expired - Fee Related JP4590417B2 (ja) 2004-01-16 2005-01-14 Ｎｐｃ１ｌ１（ｎｐｃ３）およびこのリガンドの同定方法

Country Status (6)

Country Link
US (1) US7901893B2 (https=)
EP (1) EP1723414A4 (https=)
JP (1) JP4590417B2 (https=)
CA (1) CA2553769C (https=)
MX (1) MXPA06008124A (https=)
WO (1) WO2005069900A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN100471835C (zh) 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
EP1893222A4 (en) * 2005-06-15 2010-07-07 Merck Sharp & Dohme ANTI-HYPERCHOLESTERINAMIC COMPOUNDS
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2173893A4 (en) * 2007-06-28 2010-07-21 Merck Sharp & Dohme USE OF MDCK CELLS IN THE ASSESSMENT OF CHOLESTEROL MODULATORS
CN101580871B (zh) * 2008-05-13 2013-06-05 中国科学院上海生命科学研究院 基于分析npc1l1蛋白亚细胞定位变化筛选降胆固醇新药的方法
CN102869382A (zh) * 2010-06-10 2013-01-09 (株)Ad生物技 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物
WO2016179212A1 (en) * 2015-05-05 2016-11-10 Albert Einstein College Of Medicine, Inc. Antibody therapeutics against filovirus infections and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561227A (en) * 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
ES2107548T3 (es) * 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
FI960095L (fi) * 1993-07-09 1996-01-09 Schering Corp Menetelmä atsetidinonien syntetitoimiseksi
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU8286998A (en) * 1997-07-03 1999-01-25 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Genes for niemann-pick type c disease
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
HK1039487B (en) 1998-12-07 2005-08-12 Merck Sharp & Dohme Corp. Process for the synthesis of azetidinones
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
ATE549412T1 (de) 1999-04-05 2012-03-15 Schering Corp Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
WO2000063703A1 (en) * 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1273657A4 (en) 2000-03-24 2005-04-06 Takeda Pharmaceutical NEW PROTEIN, METHOD FOR ITS PRODUCTION AND ITS USE
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EE05453B1 (et) * 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
WO2003100094A2 (en) 2002-05-23 2003-12-04 Devgen Nv Method for determining the influence of a compound on cholesterol transport
CA2492017A1 (en) * 2002-07-19 2004-01-29 Schering Corporation Npc1l1 (npc3) and methods of use thereof
US20040132058A1 (en) * 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040137467A1 (en) * 2002-07-19 2004-07-15 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
RU2345089C2 (ru) 2002-08-06 2009-01-27 Санофи-Авентис Дойчланд Гмбх ОЧИЩЕННЫЙ 145 кДа-БЕЛОК, СПОСОБНЫЙ СВЯЗЫВАТЬ ХОЛЕСТЕРИН И/ИЛИ ИНГИБИТОРЫ ПОГЛОЩЕНИЯ ХОЛЕСТЕРИНА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ОЧИСТКИ И ПРИМЕНЕНИЕ 145 кДа-БЕЛКА
EP1562605A4 (en) 2002-10-08 2006-07-12 Massachusetts Inst Technology COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT
WO2005069900A2 (en) 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
CA2579790A1 (en) 2004-07-30 2006-02-09 Mount Sinai School Of Medicine Of New York University Npc1l1 and npc1l1 inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2007526998A5 (https=)
JP5700911B2 (ja) 配向され、固定化された巨大分子を含む組成物とその製造法
JP2014532430A5 (https=)
JP2006517985A5 (https=)
JP2004514139A5 (https=)
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
JP2007517217A5 (https=)
DE602006019111D1 (de) Verfahren zur isolierung von analyten aus einer probe
ATE502117T1 (de) Nanopartikel mit gebundenen oligonukleotiden und deren verwendungen
WO2005023986A3 (en) Microrna as ligands and target molecules
WO2004074310A8 (en) Mycobacterial diagnostics
ATE449337T1 (de) Assay
JP2007505908A5 (https=)
ATE373235T1 (de) Fluoreszensanalyseelement mit der anwendung eines metallischen nanolochs und verfahren zur herstellung desselben
DE602005022797D1 (de) Silanmoleküle mit voraktivierten und Protein-resistenten Funktionalitäten sowie diese enthaltende Silanschichten
CN103935985A (zh) 石墨烯纳米网和在石墨烯片中形成孔的方法
Campuzano et al. Tailoring sensitivity in electrochemical nucleic acid hybridization biosensing: Role of surface chemistry and labeling strategies
ATE548467T1 (de) Verfahren zur identifizierung von biomarkern mit eignung bei der diagnose biologischer zustände
EP3828284A1 (en) One-step procedure for the purification of nucleic acids
WO2005069900B1 (en) Npc1l1 (npc3) and methods of identifying ligands thereof
JP2007523644A5 (https=)
ATE333522T1 (de) Verfahren zur bestimmung von mehrere analyten
JP2007532632A5 (https=)
DE60219809D1 (de) Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
JP2005538360A5 (https=)